Dolan Matthew Vincent 4
4 · DEXCOM INC · Filed Mar 6, 2023
Insider Transaction Report
Form 4
DEXCOM INCDXCM
Dolan Matthew Vincent
EVP, Strategy & Corporate Dev
Transactions
- Sale
Common Stock
2023-03-06$114.40/sh−226$25,854→ 26,536 total
Footnotes (2)
- [F1]On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- [F2]Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023.